Embecta 第四季度收益超出预期，但股价下跌;分析师仍然上调了该股。 Embecta beat Q4 earnings expectations but saw stock fall; analysts still upgraded the stock.

糖尿病溶液公司Embetta报告说,Q4的收益为每股0.65美元,比分析师的预期高出0.20美元。 Embecta, a diabetes solutions company, reported Q4 earnings of $0.65 per share, beating analysts' expectations by $0.20. 尽管收入节减,股票价格却跌至17.56美元。 Despite the earnings beat, the stock price fell to $17.56. 该公司宣布季度股息为每股0.15美元,并将2025财政年度指南更新为2.700-2900 EPS。 The company announced a quarterly dividend of $0.15 per share and updated its FY 2025 guidance to 2.700-2.900 EPS. 分析师已经升级了Embecta的股票, 摩根士丹利设定了20美元的价格目标和BTIG研究26美元的目标. Analysts have upgraded Embecta's stock, with Morgan Stanley setting a $20.00 price target and BTIG Research a $26.00 target.